STOCKHOLM, SWEDEN – October 25, 2012. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that results from a new study were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine® kit, are associated with a high risk for vein graft failure after bypass surgery.
It is known from previous published studies that low plasma levels of antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as well as to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke in healthy individuals. Professor Michael Sobel of the Division of Vascular Surgery, VA Puget Sound HCS and the University of Washington, Seattle, USA, and his colleagues have now conducted a pilot, prospective, observational study in patients undergoing vein bypasses for...